Latest News
Pfizer reports Phase 3 TALAPRO-3 results showing improved outcomes in metastatic prostate cancer
19 March 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Thursday announced positive topline results from the Phase 3 TALAPRO-3 study evaluating TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) in patients with homologous...
Glaukos launches Epioxa to advance incision-free treatment for keratoconus
19 March 2026 - Ophthalmic pharmaceuticals and medical technology company Glaukos Corporation (NYSE:GKOS) announced on Thursday the commercial availability of Epioxa HD / Epioxa, a topical therapy for the treatment of keratoconus, a rare, sight-threa...
bioMérieux secures IVDR CE marking for respiratory diagnostic panels in Europe
19 March 2026 - French diagnostics company bioMérieux (Euronext Paris:BIM) said on Thursday that it has obtained IVDR CE marking for its BIOFIRE SPOTFIRE Respiratory/Sore Throat plus (R/STplus) Panel and Panel Mini, enabling near-patient diagn...
Specific Biologics and Western University win grant to develop ML platform to accelerate development of Dualase-based therapeutics 
19 March 2026 - Canadian biotechnology company Specific Biologics Inc announced on Wednesday that together with Western University it has been awarded a grant of more than CAD1.8m from Genome Canada and Ontario Genomics Genomic Applications Partnersh...
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
19 March 2026 - Swedish life science tools company Mabtech announced on Wednesday a strategic collaboration with Sai Life Sciences, a global Contract Research Organisation (CRO).Under the agreement, Sai's Boston discovery laboratory will serve a...